The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2015 | New era for monoclonal antibody-based immunotherapy for treating multiple myeloma
At the 20th Congress of the European Hematology Association (EHA), Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta, GA, reviews the development of immunotherapy using monoclonal antibodies (mAbs) for the treatment of patients multiple myeloma. He focuses on the basic and clinical aspects of the emerging and promising novel mAbs, daratumumab, which targets CD38, and elotuzumab, which targets signaling lymphocytic activation molecule-F7 (SLAMF7).
